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sary antibiotic use. Public health campaignsmayhave an important role in improv-
ing appropriate antibiotic prescribing.
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OBJECTIVES: To estimate the potential unmet need for Magnetic Resonance Imag-
ing (MRI) amongMedicare patients with pacemaker implants, via the prevalence of
diagnoses and conditions for which MRI is the preferred investigation method.
METHODS: The data analyzed comprised of fee-for-service portion of the 2008
Medicare patient population. Using this sample, two issues were examined: the
prevalence of the diseases forwhichMRI is the preferred imagingmodality, and the
uptake rates of all imaging modalities for MRI-indicated beneficiaries with pace-
maker implants compared with those having no implants. For each of those dis-
eases for which MRI is the preferred modality we also identified any trade-offs
between lower MRI rates and higher rates for other imaging modalities in pace-
maker-implanted compared with non-implanted patients. RESULTS: There was
almost no use of MRI in the pacemaker-implanted population, whereas 13% of
patients without any kind of implant received an MRI in 2008. Clinical practice
appears in line with the contraindication for MRI in pacemaker-implanted pa-
tients. Cancer of the CNS and suspected Stroke are conditions which require
timely, accurate imaging for good therapeutic decision making. A total of 73% and
41% of non-paced subjects received whole body MRI for these conditions respec-
tively, compared with 1% of paced subjects for each disease. Similar diagnostic
discrepancies were observed for Motion disorders, Dementia, Chronic orthopaedic
pain and spinal disorders. Pacemaker implanted patients also had high rates of
co-morbidities. CONCLUSIONS: There seems to be a large unmet clinical need for
pacemakers and other implanted cardiac devices which allow MRI to be used as a
diagnostic method. The very high rate of MRI use in non-implanted patients with
acute, progressive and often fatal conditions of stroke and cancer, and its absence
of use in the same patient groups with implants is a concern. The use of MRI
conditional cardiac devices would facilitate greater diagnostic method choice.
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OBJECTIVES: The margin between the price of a drug and its reimbursement price
(yakkasa) is determined by negotiation between wholesalers and medical institu-
tions in Japan. The Ministry of Health, Labour andWelfare (MHLW) claims that the
yakkasa reflects the market value of drugs. Factors, however, influencing the yak-
kasa have not been clarified. The aim of this study was to investigate the current
status and determinants of the yakkasa of generic drugs. METHODS: The reim-
bursement price of a drug,which is determined by theMHLW in Japan, decreases in
proportion to the yakkasa every two years. To calculate the yakkasa, we used the
drug price lists of 2006, 2008, and 2010. We identified generic drugs with a higher
percentage margin for each year, and averaged the yakkasa by drugs. We then
investigated longitudinal trends in the range of the yakkasa. Furthermore, we ex-
plored factors associatedwith the larger percentagemargin. RESULTS: The generic
drugs with a higher percentage margin were: doxazosin mesilate (30.7%), famoti-
dine (29.7%), and manidipine hydrochloride (29.6%) in 2006; ofloxacin (31.1%), ceti-
rizine hydrochloride (27.4%), and actarit (25.8%) in 2008; and ofloxacin (24.1%),
cetirizine hydrochloride (23.2%), and levofloxacin (22.5%) in 2010. The yakkasa was
correlatedwith the logarithmic capital of genericmanufacturers, i.e., generic drugs
developed by larger companies had smaller margin. The coefficient of variance for
the yakkasa decreased every two years with the revision of drug prices.
CONCLUSIONS: The generic drugs prescribed frequently or developed recentlyhad
a higher percentage margin. The relationship between the yakkasa and capital
might signify the fact that more competitive manufacturers tend to paysmaller
margin, since medical institutions have no incentive to buy drugs from smaller
manufactures, unless the margin is larger.
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OBJECTIVES: China’s national pharmaceutical system has multiple Objectives: to
develop the domestic pharmaceutical industry and encourage innovation, to con-
trol total pharmaceutical expenditure (TPE) which represents the largest compo-
nent of total health expenditure (THE) in China, and to ensure equities for poor and
uninsured patients. The challenges to the current system with distorted market
incentives resulted in unaffordable drug costs and questionable prescribing prac-
tices that undermine public health. This study intended to examine the time trends
and determinants of total pharmaceutical expenditure in China.METHODS: Total
pharmaceutical expenditures over 1990-2009 were explained by amount of pre-
scriptions dispensed, proxy of health utilization, and price index over years includ-
ingmedical CPI. Data from China National Health Accounts Report was used. Time
trends of TPE as share of THE (TPE/THE) and of GDP (TPE/GDP), and the relationship
between TPE and GDP were examined descriptively. The growth of TPE was exam-
ined after adjusting for health utilization. Determinants of TPE/THE and TPE/GDP
were investigated by time-series regression models. RESULTS: Descriptive analy-
ses showed TPE/THE and TPE/GDP grew over the years 1990-2009. THE/GDP grew
faster in the recent few years than TPE/GDP. TPE per visit still rose over years after
adjusting for health utilization (inpatient and outpatient services). However,
health utilization was not shown the growth pattern along with the GDP growth
over 1990s. Time-series analyses showed TPE/THE was negatively influenced by
GDP (p  0.039) and medical CPI (p0.021). TPE/GDP was positively influenced by
price index of prescriptions (p0.000) and amount of health service use including
inpatient (p 0.012) and outpatient visits (p0.003). CONCLUSIONS: Both TPE and
THE increased over timewith the pace of GDP growth. The study provided evidence
of increasing economic burden on patients imposed by TPE in China. Rapid growth
in the China economy, however, may ameliorate the overall TPE burden.
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OBJECTIVES: To evaluate the quality and improve the quality control of vaccine
refrigerators at primary care units; PCU. METHODS: It was a quasi-experimental
study; pre-post intervention descriptive designwas studied. Computerized Transit
temperature data loggers were used to monitor vaccine refrigerator temperatures
at 19 PCU under the authority of Songkhla hospital. Data loggers, monitoring tem-
peratures from 40 0C to 850C, were programmed to record every 30 minutes for
15 days. Percentage of frequency which temperatures were out of 2-8 0C range and
maximum/minimum temperatures had been used for this evaluation. Results of
the study were sent back to PCU for adjustment.Post adjustment data were col-
lected for assessment RESULTS: Vaccine Refrigerators at PCU were household
models.Refrigerator ages average is 7.37 years. Before intervention, average per-
centage of frequency, which temperatureswere2 0 C and 8 0 C, was 13 .76% and
2.03% (range 0%-81% and 0%-11.23% respectively).19 units recorded temperatures
below 2 0 C and above 8 0 C at one point. The lowest and highest temperatures
recorded were 26.20 0 C and -70C. After assessment, 8 units required modifications
and 11 units got new refrigerators. Refrigerators age average was 2.68 years. Aver-
age percentage of frequency, temperatures2 0 C and 8 0 C, was 3.31% and 0.88%
(range 0%-51.48% and 0.88%-5.34% respectively). 6 units had no out of range tem-
peratures. The lowest and highest temperatures were -2.5 0 C and 190C. The per-
centage of frequency was decreased in 18 units but not statistically significant.
However, the lowest and highest temperatures was statistically significant de-
creased (p-value  0.004, 0.013 respectively) CONCLUSIONS: Using data logger
feedback can help maintain vaccine cold chain standard (2-8 0C). A data logger
should be used continually to monitor temperature in a vaccine refrigerator.
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OBJECTIVES: Affordability is one of the main objectives of national drug policies
but there are no clear indicators to determine whether a medicine is affordable.
The share ofmedication in consumer basket, comparing to GrossDomestic Product
(GDP) per capita and comparing to the daily income of the lowest paidworker in the
government have been some methods to judge about the affordability. This study
tries to investigate affordability of antibacterial therapy in Iran during last decade
(2001-2010). METHODS: Annual sales of antibacterial medicines for systemic use
(J01 based on ATC classification) were gathered from Ministry of Health and were
crosschecked by sample data from suppliers and distributors. The cost of medi-
cines according to DDD (Defined Daily Dose) was calculated in Iranian Rials (IRR)
and Dollars (USD) based on average exchange rate in each year. These costs were
compared to GDP per capita, the salary of lowest paid worker in MOH and standard
cost of household basketwhich officially announced by the central bank. RESULTS:
Tetracyclines (J01A) and Sulfonamides (J01E) were the cheapest antibacterial treat-
mentswhile Amphenicoles (J01B) and unclassified antibacterials such as Vancomi-
cine (J01X) were themost expensive treatment for bacterial infections. The average
cost of antibacterial medicines was 0.3USD/DDD which equals to 3.5% of daily
income of the lowest paid worker and 2.5% of daily GDP/capita. The trend of com-
parative costs did not show any significant changes during the period.
CONCLUSIONS: A moderate growth was observed in daily cost of antibacterial
therapy while IRR is the unit of measurement. But when the currency changes to
USD or when costs compare to daily income of the lowest paid worker or to GDP/
Capita, No growth was observed. Apart from changes of the trends, the cost of
antibacterial therapy was too cheap to put a catastrophic expense on the health
system.
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Establishing essential medicine policy (EMP) is one of 5 health system reform pil-
lars in China in 2009. After three-year implementation, the strengthens and weak-
nesses of EMP need to be monitoring and evaluation. OBJECTIVES: The paper re-
views the process of listing, pricing, purchasing, utilization and reimbursement of
essentialmedicines and discusses the achievements and issues of EMP.METHODS:
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The EMLs are collected and compared from 31 provinces; the indictors of EDP are
evaluated before and after implementation. RESULTS: Although national EDL only
contains 307 essential medicines, the number of added EMs in provincial EDL are
various from 64 through 455. The zero-markup policy of EDs conducted in public
grass-roots health facilities (urban community health centers and rural township
hospitals) have reached to 98.8%. More than 95% EDs can be reimbursement by
medical insurance schemes. The average percentage of price cutting was 25%-50%
after tender bidding and purchasing. Quality assurance and sufficient provision of
ED became a problem. The number of essential medicines is still not meet the
needs of outpatients so that patients flow back to the secondary and tertiary hos-
pitals, the financial subsidies from government usually are not supported timely.
Along with the expansion of EDP in village health posts and hospitals, how to
incentive and maintain the income level of health professionals have to be
considered. CONCLUSIONS: To promote the EMP, the adjustment of EDL is required in
2012. The criteria of selectiononessentialmedicines inprovincial level shouldbeunified.
The implementationof EMPwill notbe successful invillageandurbanhospital leveluntil
solving the problemof remuneration and payment system in health settings.
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OBJECTIVES: To compare health expenditure as total % of GDP, per capita PPP and
inUS dollars aswell as total drug expenditurewith top tenATC groupswith highest
expenditure in 2009 and 2010 in Bosnia & Herzegovina (B&H) and Croatia (CRO).
METHODS: Research was based on data published in latest official annual reports
from two national Drug Agencies, from B&H and CRO, and official reports from The
World Bank. Analysis was performed for all drugs and top ten ATC groups were
identified and compared in both countries for two years – 2009 and 2010. RESULTS:
The Health expenditure; total (% of GDP) in B&H was 10.94 in 2009 (10.31 in 2008),
CRO - 7.83 in 2009 (7.83 in 2008). In 2009, total drug expenditure in B&H was 238.8
mil EUR compared to 269 in 2010 (increase of 11,23%), while in CRO in 2009 it was
625.6 mil EUR compared to 664.5 in 2010 (increase of 5,85%). Top 10 ATC 1st level
drug groups with highest expenditure in both countries in 2009 and 2010 were
rather similar but on ATC 2nd level we observed significant differences in the share
of relevant ATC groups with leading C09, J01 and L01 for 2009 and C09, J01 and A10
for 2010 in B&H. Leading groups in CRO for 2009 were L01, J01 and C09, and for 2010
J01, C09 and L01. No drugs from C10 group were present in top ten ATC 2nd level in
B&H as well as R03 in 2009 and 2010 unlike the CRO. CONCLUSIONS: CRO has a
stable total health expenditure and universal health care system with twice
smaller increase in total drug expenditure compared to B&H. B&H is a country with
decentralized health care system including drug politics and positive reimburse-
ment drug lists which need to be equalized.
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OBJECTIVES: As part of the Affordable Care Act of 2010 (ACA), smoking cessation
medications (SCMs) including bupropion, varenicline, and nicotine-replacement
drugs, will be provided at no cost to people with health insurance. However, the
scope of the potential impact of this policy was unclear. This study explored which
populations would benefit from this mandate. METHODS: A retrospective cross-
sectional study using the nationally representativeMedical Expenditure Panel Sur-
vey 2009 was conducted. Adults who currently smoke, advised by doctors to quit
smoking, or diagnosed tobacco-use disorderswere extracted for analysis (weighted
N40,095,913). Chi-square tests and one-way ANOVAswere conducted to examine
the heterogeneity in SCM use and related out-of-pocket expenses with respect to
socio-demographic factors. A logistic regression was performed to examine the
associations between socio-demographic factors and SCM use. All analyses were
weighted based on complex survey design. RESULTS: Of the 40,095,913 smokers,
only 3.1% of them used SCMs in 2009, whereas 52.1% were advised by doctors to
quit smoking. Chi-square analyses revealed significant differences in SCM use
based on race/ethnicity, relationship status, health insurance status, HMO status,
perceived mental health status, and comorbid depressive/bipolar disorders (all
p0.001). Uses in buprorion and varenicline also varied with health insurance sta-
tus (both p0.05). There were significant differences in out-of-pocket expense for
SCMs between smokerswith different insurance status, with the uninsured paying
the highest out-of-pocket price (p0.001). The logistic regression revealed that
non-Hispanic blacks were less likely to take SCMs compared with Hispanics
(OR0.30, p0.01). CONCLUSIONS: Cost is a substantial barrier to SCM use among
smokers.Once thisbarrier is liftedwith theACA,manysmokerswhodonotcurrentlyuse
SCMsare likely touseSCMsunless theyhaveunfavorableattitudes towardsSCMuseand
smokerswho currently use SCMsmight switch tomore effective but expensive SCMs.
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OBJECTIVES:This paper proposes, based on a theoretical framework for estimating
demand functions under uncertainty, to highlight the importance of including
economic variables of market operation and actors strategic organization in the
design of regulations on the pharmaceutical sector. They can contribute beyond
the value of pharmacological and clinical tools in the specification of standards
within a framework of evidence-basedmedicine and the dynamic analysis of cost-
effectiveness in decisionmaking froman institution of sectoral superintendence of
social insurance. METHODS: With a database of 9147 and 27647 comments on
covered population prescriptions by social security in Argentina, we analyze the
therapeutic groups of hypertensive and lipid lowering, respectively, by the classical
least squares estimation and logistic models for each product. RESULTS: The data
provide consistent messages about the presence of differentiation mechanisms
that overshadow the traditional negative relationship between price and sales. In
particular, the interaction between brand and drugs, which can be extended to
technological changes in a dynamic context, implies a complementary perspective
in designing the regulatory framework. CONCLUSIONS: The power of negotiation
and establishment of rules of producersmust be considered in eachparticular case,
to coordinate incentives to encourage rational behavior in prescribing, moving in a
pattern of more cost-effective.
PHP18
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OBJECTIVES: There is a need as well as a demand for understanding the influences
that are changing the landscape in terms of pharma management in the Middle
Eastern region. This research is focussed on theUAE, one of the pioneers of a formal
pharmaceutical assessment, to understand drivers of reform and implications.
METHODS: Initial desk research was conducted to understand trends in reim-
bursement decisions and pricing of drugs. This was followed by in-depth inter-
views with 4 stakeholders in the Emirati system to understand historical influ-
ences, current trends, drivers for decision making and future changes expected.
These data were analysed qualitatively to produce results. RESULTS: All respon-
dents (n4) thought of the UAE as one of the regional pioneers of adopting West-
ern-style pharmaceuticals management systems. The imminent introduction of
US-style PBMs is likely to be a major step in this direction. In addition, the govern-
ment are working on the development of a centralised patient record that will
include GCC/ME countries. This will help providers access patient history easily,
prescribe more efficiently, avoid medication errors amongst other things. The in-
creasing cost of drugs associated with the universal health insurance system (dou-
bled national fund for the purchase of medicines this year) along with the high use
of imported drugs was thought to be the most important driver for reform by
majority of the respondents (n3). All respondents were aware of the regional
influence of the UAE reforms. CONCLUSIONS: P&R of pharmaceuticals is expected
to move from a chaotic system to a more transparent, regulated one that requires
submission of PE evaluations and clinical evidence. The MOH has already started
developing a patient registry to assess validity claims from manufacturers. In a
country where most of the drugs are imported due to lack of local manufacturing
capabilities, it will become an increasingly important market for international
manufacturers.
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OBJECTIVES: To analyze the consumption of medicines for the treatment of peptic
ulcer and gastroesophageal reflux disease (ATC subgroup A02B) in Serbia in corre-
lation with Norway. METHODS: Data on drug utilization in 2009 have been pro-
vided by the annual reports of the Agency for Drugs and Medical Devices of the
Republic of Serbia and the Norwegian Institute for Public Health. The results were
expressed as the number of defined daily doses per 1000 inhabitants per day (DDD/
TID). A qualitative analysis was carried out according to the Drug Utilization 90%
(DU90%) approach. RESULTS: The overall consumption of medicines for peptic
ulcer and gastroesophageal reflux disease was twofold lower in Serbia than in
Norway (21.16 DDD/TID vs. 42.31 DDD/TID). Histamine H2-receptor antagonists
accounted for 73% (15.43 DDD/TID) of A02B medicines consumption in Serbia ver-
sus 14% (6.11 DDD/TID) in Norway. Whereas in Serbia, proton pump inhibitors
participatedwith 26.26% (5.56 DDD/TID)within A02B subgoup utilization, the share
of these medicines in Norway was 84.42% i.e. 35.72 DDD/TID. Within DU90% seg-
ment, 4 (of 7) medicines have been found in Serbia and 5 (of 10) in Norway. The
most commonly used medicines within A02B subgroup in Serbia were ranitidine
(60.9%, 12.9 DDD/TID), omeprazole (12.7%, 2.69 DDD/TID), famotidine (11.9%, 2.53
DDD/TID), and pantoprazole (7.7%, 1.63 DDD/TID), whilst in Norway were esome-
prazole (33.9%, 14.34 DDD/TID) followed by pantoprazole (19.3%, 8.18 DDD/TID),
omeprazole (15.7%, 6.67 DDD/TID), lansoprazole (15.4%, 6.53 DDD/TID) and raniti-
dine (10.6%, 4.51 DDD/TID).CONCLUSIONS: Besides the quantity, the pattern of use
of medicines for peptic ulcer and gastroesophageal reflux disease showed differ-
ences between observed countries. Differences in prescription regulations, price
and reimbursementmost likely influenced the type and amount of medicines con-
sumed.
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